Chimerix Appoints Marc D. Kozin to Board of Directors
March 21, 2024 at 07:00 am EDT
Share
Chimerix announced the appointment of Marc D. Kozin as the newest member of the Company?s Board of Directors. In addition, Patrick Machado has announced his retirement from the Chimerix Board effective at the Company?s 2024 Annual Meeting of Stockholders in June, after ten years of service. Mr. Kozin brings more than 35 years of experience in corporate and business strategy consulting, merger and acquisition advisory services, and value management.
Mr. Kozin previously served as President of L.E.K., a global strategy consulting firm, where he established the Boston office and led the development of the firm?s industry leading life science strategic planning practice. He currently serves on the Board of Directors of UFP Technologies and HCRx Holdings. Mr. Kozin holds a B.A. in Economics from Duke University and an M.B.A. from The Wharton School, University of Pennsylvania.
Chimerix, Inc. is a biotechnology company. The Company is focused on developing medicines that address unmet medical needs. The Company's product Imipridones is a cancer therapy that provides ONC201, which is in clinical-stage development for H3 K27M-mutant glioma as its lead indication. In addition, imipridone ONC206 is in dose-escalating clinical trials. Imipridones target specific G protein-coupled receptors (GPCRs) and mitochondrial caseinolytic protease P (ClpP), resulting in cancer cell death. The Company's product Imipridone chemical scaffold provides an opportunity to target GPCRs and ClpP with differential specificity and function. Its ONC212 is an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Its CMX521 is a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides, also includes approximately 3,500 nucleosides.